Last reviewed · How we verify
NCT06573723
Institutional Registry of Rare Diseases
trial in Rare Diseases in 380 participants. Currently enrolling.
31 December 2034
Quick facts
| Lead sponsor | Hospital Italiano de Buenos Aires |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 380 |
| Start date | 1 July 2024 |
| Primary completion | 31 December 2034 |
| Estimated completion | 31 December 2034 |
| Sites | 1 location across Argentina |
Conditions studied
- Rare Diseases — all drugs for Rare Diseases →
- Amyloidosis — all drugs for Amyloidosis →
- Sarcoidosis — all drugs for Sarcoidosis →
- Phacomatosis — all drugs for Phacomatosis →
Sponsor
Hospital Italiano de Buenos Aires
Who can join
Eligibility, any sex, with Rare Diseases or Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD). Moreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06573723
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rare Diseases
Currently open trials in the same condition.
- NCT06595940 — Genetic Analysis of Uncommon Disease Presentations in Non-US Populations · recruiting
- NCT07247279 — Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia · recruiting
- NCT07102966 — Genetic Study to Determine the Cause of Birth Defects in Newborns in Texas · NA · recruiting
- NCT06856902 — BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe · NA · recruiting
- NCT06926127 — Genomic Profiling of Genetic and Rare Diseases · NA · recruiting
Other Hospital Italiano de Buenos Aires trials
Trials by the same sponsor.
- NCT07397416 — Impact of Implementing a Rapid PCR-based Algorithm for Carbapenemase-producing Enterobacterales (CPE) and Infection Cont · NA · not yet recruiting
- NCT07167173 — Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis · not yet recruiting
- NCT06683781 — Ventilatory Settings and Monitoring Variables Associated With Weaning Failure in Critically Ill Patients · recruiting
- NCT06609798 — Ultrasound Assessment During Weaning from Mechanical Ventilation · enrolling by invitation
- NCT06419296 — Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam V · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06573723 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Italiano de Buenos Aires
- Last refreshed: 14 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06573723.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing